doi:10.19982/j.issn.1000-6621.20230132

Abstract

CLC Number:

R563

Figures/Tables 3

References 19

[1]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1): 2000535. doi:10.1183/13993003.00535-2020. doi: 10.1183/13993003.00535-2020
[2]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[3]	Ratnatunga CN, Lutzky VP, Kupz A, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol, 2020, 11: 303. doi:10.3389/fimmu.2020.00303. doi: 10.3389/fimmu.2020.00303 pmid: 32194556
[4]	Li W, Yazidi A, Pandya AN, et al. MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections. Front Microbiol, 2018, 9: 1547. doi:10.3389/fmicb.2018.01547. doi: 10.3389/fmicb.2018.01547 pmid: 30042757
[5]	Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis, 2016, 45: 123-134. doi:10.1016/j.ijid.2016.03.006. doi: 10.1016/j.ijid.2016.03.006 pmid: 26976549
[6]	Raju RM, Raju SM, Zhao Y, et al. Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease. Emerg Infect Dis, 2016, 22(3): 365-369. doi:10.3201/eid2203.151643. doi: 10.3201/eid2203.151643 pmid: 26886068
[7]	Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review. Chest, 2018, 153(4): 888-921. doi:10.1016/j.chest.2018.01.024. doi: 10.1016/j.chest.2018.01.024 URL
[8]	Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis, 2018, 18(1): 206. doi:10.1186/s12879-018-3113-x. doi: 10.1186/s12879-018-3113-x
[9]	Preiss L, Langer JD, Yildiz Ö, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv, 2015, 1(4): e1500106. doi:10.1126/sciadv.1500106. doi: 10.1126/sciadv.1500106
[10]	Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med, 2018, 6(9):699-706. doi:10.1016/S2213-2600(18)30235-2. doi: 10.1016/S2213-2600(18)30235-2 pmid: 30001994
[11]	首都医科大学附属北京胸科医院, 中国防痨协会非结核分枝杆菌分会, 中国防痨杂志》编辑委员会. 非结核分枝杆菌病治疗药品超说明书用法专家共识. 中国防痨杂志, 2020, 42(8): 769-787. doi:10.3969/j.issn.1000-6621.2020.08.002. doi: 10.3969/j.issn.1000-6621.2020.08.002
[12]	Yu X, Gao X, Li C, et al. In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother, 2019, 63(8): e00031-19. doi:10.1128/AAC.00031-19. doi: 10.1128/AAC.00031-19
[13]	Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017, 61(10): e00900-17. doi:10.1128/AAC.00900-17. doi: 10.1128/AAC.00900-17
[14]	Kim DH, Jhun BW, Moon SM, et al. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother, 2019, 63(8): e00665-19. doi:10.1128/AAC.00665-19. doi: 10.1128/AAC.00665-19
[15]	Gil E, Sweeney N, Barrett V, et al. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV. Emerg Infect Dis, 2021, 27(3): 944-948. doi:10.3201/eid2703.202359. doi: 10.3201/eid2703.202359 pmid: 33622490
[16]	Erber J, Weidlich S, Tschaikowsky T, et al. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report. BMC Infect Dis, 2020, 20(1): 365. doi:10.1186/s12879-020-05075-7. doi: 10.1186/s12879-020-05075-7
[17]	Chan WY, Ho PL, To KK, et al. A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and clofazimine. Int J Infect Dis, 2021, 103: 9-12. doi:10.1016/j.ijid.2020.10.102. doi: 10.1016/j.ijid.2020.10.102 URL
[18]	Muliaditan M,Della Pasqua O. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. Br J Clin Pharmacol, 2021, 87(1):140-151. doi:10.1111/bcp.14371. doi: 10.1111/bcp.14371 URL
[19]	Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72(Suppl 2): ii1-ii64. doi:10.1136/thoraxjnl-2017-210927. doi: 10.1136/thoraxjnl-2017-210927

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 19

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[2]	Zhu Jiankun, Meng Qian, Kong Kangbao, Jin Feng. The value of pneumonectomy in the treatment of pulmonary mucormycosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 274-281.
[3]	Fu Ying, Xiong Yangyang, Fang Si, Li Chuanxiang, Guo Hongrong. The research progress on the relationship between serum albumin and its derivative biomarkers and chronic obstructive pulmonary disease [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 231-236.
[4]	. [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 116-120.
[5]	Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65.
[6]	Liang Feng, Liu Deqing, Chen Hua, Chen Pinru, Tan Yaoju, Hu Jinxing, Zhang Danni, Xu Liuqing. Epidemiological characteristics of non-tuberculous mycobacterial disease in Guangzhou [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1373-1379.
[7]	Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
[8]	Tan Shouyong. Research progress on comprehensive treatment beyond antibiotic therapy for nontuberculous mycobacterium pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 967-970.
[9]	Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829.
[10]	Yang Chengqing, Chen Shufang, Mei Chunlin, Cao Tanze, Feng Wei, Liu Xiuping, Xu Wenjing, Du Ronghui. Clinical characteristics of 220 cases of pulmonary tuberculosis combined with chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 770-777.
[11]	Han Wenya, Zhou Yangyu, Wang Meifang, Xue Xinying. Progress in clinical diagnosis and treatment of pulmonary cryptococcosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 830-838.
[12]	Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755.
[13]	He Xiangrong, Chen Hua, Chen Pinru, Liang Feng, Ren Huili, Zhu Jialou, Hu Jinxing, Tan Yaoju. A case report and literature review of Mycobacterium asiaticum pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 763-769.
[14]	Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698.
[15]	Zhou Xue, He Fang, Di Yicheng, Zhang Zheng, Liu Ju. Analysis of risk factors of respiratory failure in elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 357-361.